Voyageur Pharmaceuticals Ltd. announces the closing of a subscribed private placement of more than 1 million dollars and the issuance of shares for the debt

Calgary, AB – TheNewswire – June 16, 2022: Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the “Company” Where “Traveler“) is pleased to announce that, further to its press releases dated May 26 and 31, 2022, it has completed its non-brokered private placement of units of the Company (“Units“) at a price of $0.10 per unit, issuing 11,570,000 units for total gross proceeds of $1,157,000 (the “Offer“). Each unit consists of one (1) common share (“Ordinary share“) and one (1) stock warrant (“To guarantee“) of Voyageur. Each whole warrant entitles its holder to purchase one common share at a price of $0.20 expiring two (2) years from the date of closing of the offering. The warrants include a clause Acceleration Agreement whereby, if the Common Shares trade at or above $0.30 per Common Share for a period of 10 consecutive trading days, Voyageur may accelerate the expiration of the Warrants.

The net proceeds of the Offering will be used to advance the deployment of Health Canada’s licensed products for sale in Canada.

Pursuant to the closing of the placement, Voyageur paid cash commissions to eligible unrelated parties for an aggregate amount of $37,825 and issued a total of 378,250 broker warrants entitling the holder to purchase one share common stock at a price of $0.10 per share for a period of one (1) year from the date of issue.

Completion of the Offering is subject to regulatory approval, including, but not limited to, the approval of the TSX Venture Exchange. The common shares, warrants and brokerage warrants issued will be subject to a hold period of four months from the date of closing of the offering.

Actions for debt

The Company also announces that, pursuant to its press release dated May 10, 2022, it has issued a total of 848,183 common shares at a deemed price of $0.11 per common share for the payment of outstanding debts of $93,300. owed to the Company’s creditors and unpaid debts are now extinguished.

Common shares issued by the Company have a hold period of four months and one day from the date of issue in accordance with applicable securities laws.

About Traveler

Voyageur is a Canadian public company listed on the TSXV under the symbol VM. Voyageur is focused on the development of high-performance, cost-effective barite and iodine active pharmaceutical ingredients (“APIs”) and imaging contrast agents for the medical radiology market. Voyageur’s goal is to initially generate positive cash flow from operations using third-party GMP pharmaceutical manufacturers in Canada and abroad. Ultimately, Voyageur intends to build all the necessary infrastructure to become 100% self-sufficient with all manufacturing. Voyageur holds a 100% interest in three barium sulphate (barite) projects, including the Frances Creek property, graded suitable for the pharmaceutical barite market, with interests in a high iodine brine project, lithium and bromine located in Utah, USA.

Voyageur is moving forward with its business plan to become the only fully integrated company in the medical field of radiology, controlling all primary input costs under the motto: “From the land to the bottle”.

For further media information or to arrange an interview, please contact:

Brent Willis

President and CEO

E [email protected]

www.voyageurpharmaceuticals.ca

Ron Love

CFO

Such. 403.818.6086

E [email protected]

DO NOT EXIT IN THE UNITED STATES OF AMERICA

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “1933 Act”) and may not be offered or sold in the United States United States or to or for the account or benefit of a United States company. person absent such registration or an exemption from the registration requirements of the US Securities Act and applicable United States securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Caution regarding “forward-looking” information

This press release may contain certain forward-looking information and statements, including, without limitation, the closing of the offering, statements regarding the use of proceeds and the Company’s ability to obtain the necessary Venture Exchange approvals. TSX. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of the assumptions used to prepare this forward-looking information and a description of the risk factors that could cause actual results to differ materially from the forward-looking information can be found in the Company’s disclosure documents on the SEDAR website at www. .sedar.com. Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.